Welcome to our dedicated page for Beyond Air SEC filings (Ticker: XAIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beyond Air, Inc. filings document the regulatory record for a commercial-stage nitric oxide medical device and biopharmaceutical company. Proxy materials cover stockholder votes on charter amendments, reverse stock-split authority, director elections, auditor ratification, and equity incentive plan share reserves.
Form 8-K disclosures record material events such as executive officer transitions, separation agreements, Nasdaq continued-listing compliance notices, annual meeting results, material agreements, capital-structure matters, operating and financial results, and clinical or regulatory disclosures tied to the company's nitric oxide programs.
Beyond Air, Inc. reports that it has regained compliance with Nasdaq’s minimum bid price requirement after implementing a 1-for-20 reverse stock split of its common stock on July 13, 2026.
Nasdaq confirmed compliance in an August 6, 2026 letter, based on the company’s common stock maintaining a closing bid of at least $1.00 per share for 17 consecutive trading days from July 13 through August 4, 2026. This also satisfies conditions previously set by a Nasdaq Hearings Panel for continued listing on The Nasdaq Capital Market.
The Panel imposed a Discretionary Panel Monitor for one year from the compliance letter. During this monitor period, any failure to meet a Nasdaq continued listing requirement will result in an immediate delisting determination, without the opportunity to submit a compliance plan or obtain additional time from Nasdaq staff; any appeal would go directly to the Hearings Panel.
Beyond Air, Inc. Chief Executive Officer Robert Scott Goodman purchased 34,722 shares of common stock on July 29, 2026 at $5.76 per share, bringing his direct common stock holdings to 34,822 shares. He also acquired 34,722 Series A Warrants and 34,722 Series B Warrants, each exercisable for common stock at $5.51 per share. The warrants are exercisable immediately; the Series A Warrants expire on the earlier of one year after issuance or 45 days following FDA approval of the company’s pending premarket approval supplement for LungFit PH II, while the Series B Warrants expire five years after issuance.
Beyond Air, Inc. Chief Financial Officer Daniel J. Moorhead reported purchases on 2026-07-29 of 4,340 shares of common stock at $5.76 per share, along with 4,340 Series A Warrants and 4,340 Series B Warrants, each exercisable for common stock at $5.51 per share. The Series A Warrants are exercisable immediately and expire on the earlier of one year from issuance or 45 days after FDA approval of the company’s pending premarket approval supplement for LungFit PH II, while the Series B Warrants expire five years after issuance. Following these transactions, Moorhead holds 4,340 common shares, 4,340 Series A Warrants and 4,340 Series B Warrants directly.
Beyond Air, Inc. entered into a private placement with institutional investors and insiders to raise approximately $10.2 million in upfront gross proceeds. The company will issue 167,011 common shares and pre-funded warrants for up to 1,638,835 shares, each paired with Series A and Series B common stock warrants.
The warrants cover up to 1,805,846 shares each for Series A and Series B at a $5.51 exercise price, contributing to potential aggregate proceeds of up to $30.1 million if fully exercised for cash. Pre-funded warrants are exercisable at $0.0001, subject to 19.99% ownership caps; other warrants have 9.99% caps, with expirations tied to FDA action on LungFit PH II or five years after issuance. Net proceeds are intended for working capital and general corporate purposes, and the company agreed to resale registration and temporary limitations on new equity issuances.
Lin Yi-Chien filed Amendment No. 1 to a Schedule 13G reporting beneficial ownership of 56,000 shares of Beyond Air, Inc. common stock, equal to 8.4% of that class. All reported shares are held with sole voting and sole dispositive power, with no shared authority indicated.
Beyond Air, Inc. investor Lin Yi‑Chien reported beneficial ownership of a significant block of the company’s common stock on a Schedule 13G. The report identifies Beyond Air’s common stock (CUSIP 08862L301) as the covered class of securities.
Lin Yi‑Chien is a U.S. citizen with an address in Rancho Palos Verdes, California and is shown as having sole voting and sole dispositive power over the reported Beyond Air shares, with no shared voting or dispositive power. This reflects a meaningful minority stake that is large enough to trigger beneficial ownership reporting requirements.
Beyond Air, Inc. approved and is implementing a 1-for-20 reverse stock split of its common stock. The change becomes effective at 12:01 a.m. Eastern Time on July 13, 2026, when shares begin trading on a split-adjusted basis on Nasdaq under the existing symbol XAIR.
The company is using this reverse split to raise its per-share bid price above $1.00 to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires trading at or above $1.00 for at least 10 consecutive trading days. Each stockholder’s total shares will be divided by 20 and rounded up to the nearest whole share, so no fractional shares or cash payments will result.
The company remains authorized to issue 500,000,000 shares of common stock and 10,000,000 shares of preferred stock, and the par value of both classes is unchanged. Management states that stockholders’ percentage ownership and voting power should remain essentially the same, aside from minor adjustments from rounding.
Beyond Air, Inc. reported strong growth for its fiscal year ended March 31, 2026 and announced a change in fiscal year-end to December 31. Full-year revenue rose 107% to $7.7 million, while net loss narrowed to $33.2 million, or $4.01 per share, from $46.6 million.
For the March quarter, revenue increased 66% to $1.9 million and gross margin turned positive, but the company still recorded a quarterly net loss of $10.3 million. Operating expenses fell sharply year-over-year as research and development and general and administrative costs declined.
Beyond Air ended March 31, 2026 with $17.3 million in cash, cash equivalents, restricted cash and marketable securities and $21.6 million of total long-term debt. The company issued revenue guidance of $8 million for calendar 2026 and $16–$18 million for 2027, assuming commercial launch of its second-generation LungFit PH system.
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company focused on nitric oxide (NO) technologies. Its LungFit® platform generates NO from ambient air for respiratory uses, led by LungFit® PH, which has FDA premarket approval for treating persistent pulmonary hypertension of the newborn and CE mark approval in Europe for broader pulmonary hypertension indications.
The company is commercializing LungFit® PH in the U.S., has regulatory approvals in more than 27 countries outside the U.S. and EU, and distribution agreements covering over 40 countries. Pipeline devices include LungFit® PRO for viral pneumonias and bronchiolitis, and LungFit® GO for nontuberculous mycobacterial lung infections, all using high-concentration NO to target infections. Beyond Air’s majority-owned affiliate Beyond Cancer is developing ultra-high concentration NO (UNO) for solid tumors, having completed a Phase 1 trial, while NeuroNOS is advancing selective nNOS inhibitors for autism spectrum disorder and glioblastoma, with two FDA orphan drug designations. The company’s auditor has expressed substantial doubt about its ability to continue as a going concern, and management highlights the need for additional capital and strict compliance with its loan agreement.
Beyond Air, Inc. stockholders approved giving the board discretion to implement a reverse stock split within a range of 1-for-2 to 1-for-20, with no change to authorized share counts. At the June 18, 2026 special meeting, 5,177,506 votes were cast in favor, 1,222,793 against and 87,461 abstained, from 12,692,684 shares outstanding as of the April 20, 2026 record date.
Immediately after the vote, the board approved a specific 1-for-20 reverse split ratio, combining every 20 outstanding shares of common stock into one share, to be effected after a certificate of amendment becomes effective. The company states it intends to use the split to increase its share price above $1.00 for at least ten trading days to regain compliance with Nasdaq Listing Rule 5550(a)(2) by July 31, 2026, while cautioning there is no assurance the split will be implemented as planned or achieve the desired effects.